Astrazeneca Pharma India Ltd Share Price Today - Astrazeneca Pharma India Ltd Stock Price Live NSE/BSE

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN BSE: 506820

₹8609.50

(-0.99%)

Mon, 25 May 2026, 02:12 am

MTF 5xInvest in Astrazeneca Pharma India Ltd with 5x Leverage Buy with MTF

Market Cap217.19B

PE Ratio107.14

Dividend0.37

Health Technology

Pharmaceuticals: Major

24.5K

Astrazeneca Pharma India Share Price Live Chart

1 Day

(-0.99%)

No Result Found

Summary

Market Cap
21510.63
Net Profit
115.74
P/B
27.93
Sector P/E
45.26
P/E
185.88
EV/EBITDA
106.24
Debt/Equity (Industry)
0.08
Interest Cover (Industry)
42.77
ROCE (Industry)
23.88
RONW (Industry)
19.04
ROE
23.63
ROCE
32.94
Debt/Equity
0.03
EPS (TTM)
83.21
Dividend Yield
0.37
Book Value
319.60
Interest Cover
174.17

Analysis

all

Pros

AstraZeneca Pharma India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
AstraZeneca Pharma India is profitable, therefore cash runway is not a concern.
AstraZeneca Pharma India is profitable, therefore cash runway is not a concern.
AstraZeneca Pharma India has no debt, it does not need to be covered by operating cash flow.
AstraZeneca Pharma India has no debt, it does not need to be covered by short term assets.

Cons

AstraZeneca Pharma India is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of AstraZeneca Pharma India's dividends as it is not paying a notable one for India.
AstraZeneca Pharma India is not paying a notable dividend for India, therefore no need to check if the payments are stable.
AstraZeneca Pharma India's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
AstraZeneca Pharma India's dividend is below the markets top 25% of dividend payers in India (3.08%).

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	75	75	75	75	75
FII	2.78	2.71	2.74	3.03	2.89
DII	5.80	5.56	5.26	4.56	4.65
Public	16.42	16.73	17.00	17.41	17.46
Government	0	0	0	0	0

Technical Analysis

RSI

55.39

MACD

58.98

50 DMA

8367.47

200 DMA

8767.50

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	10918.50	9570	8891.50	8221.50	7543	6873	5524.50
Fibonacci	9570	9054.87	8736.63	8221.50	7706.37	7388.13	6873
Camarilla	8583.84	8460.23	8336.61	8221.50	8089.39	7965.77	7842.16

Pivots Level: Classic

+2697

10918.50

+1348.50

9570

+670

8891.50

8221.50

Pivot Point

LTP: 8587.50

-678.50

7543

-1348.50

6873

-2697

5524.50

Moving Average

SMAEMA

Period

Value

10-EMA
8528.37
20-EMA
8472.01
30-EMA
8448.50
50-EMA
8454.59
100-EMA
8539.75
200-EMA
8554.77

Announcement Date	Purpose	Action	Ex Date
11 Feb 2026	board-meetings	Quarterly Results
07 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
28 Jul 2025	agm
18 Jun 2025	dividend	Dividend - Rs. - 32	18 Jul 2025
30 May 2025	dividend	₹32.00 Dividend /Share	18 Jul 2025
16 Jul 2024	agm
05 Jun 2024	dividend	Final Dividend - Rs. - 24	05 Jul 2024
27 May 2024	dividend	₹24.00 Dividend /Share	05 Jul 2024
22 Jul 2023	agm
14 Jun 2023	dividend	Dividend - Rs. - 16	14 Jul 2023

Astrazeneca Pharma India Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd

Cipla Ltd

Astrazeneca Pharma India Ltd About

Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinicaltrial services to an overseas group company.(Source : 202503-Annual Report Page No:148)

Industry

Pharmaceuticals - Multinational

Founded

1979

Headquarters

CEO

Shilpa Divekar Nirula

Employees

Contact

Website

http://www.astrazeneca.in

comp.secy@astrazeneca.com

Phone

91-080-67748000

Location

Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road, Bangalore, Karnataka, 560045

Year	History
2018	AstraZeneca Pharma India Ltd receives DCGI permission for Durvalumab.
2021	AstraZeneca partners with DocOn to digitize healthcare clinics across India. AstraZeneca and Rajiv Gandhi Cancer Institute launch Project Chariot for CLL diagnosis and treatment. AstraZeneca launches Clinical Data and Insights division in India.
2022	AstraZeneca Pharma receives CDSCO approval for Dapagliflozin tablets.
2023	AstraZeneca inaugurates Centre of Excellence at Manipal Hospital Goa for severe asthma patients. AstraZeneca India partners with Roche Diagnostics India to improve breast cancer diagnostic testing. Government of Karnataka signs MoU with AstraZeneca India to accelerate lung cancer testing.
2024	AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announce collaboration for exclusive distribution of Symbicort in India. AstraZeneca India receives CDSCO approval for Durvalumab additional indication. AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru. AstraZeneca receives CDSCO approval to import and market Andexanet Alfa for critical bleeding conditions.

Client Name	Deal Type	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	bulk	Buy	125166	7884.41	07 Oct 2024
GRAVITON RESEARCH CAPITAL LLP	bulk	Sell	125166	7887.16	07 Oct 2024
GRAVITON RESEARCH CAPITAL LLP	bulk	Sell	127119	7804.96	30 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	bulk	Buy	127119	7802	30 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	bulk	Buy	131308	7499.17	24 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	bulk	Sell	131308	7506.36	24 Sept 2024
ISHARES CORE EMERGING MARKETS MAURITIUS CO	block	Sell	74097	3152.55	19 Sept 2022
ISHARES CORE MSCI EMERGING MARKETS ETF	block	Buy	74097	3152.55	19 Sept 2022
ISHARES INDIA SC MAURITIUS COMPANY	block	Sell	6542	3152.55	19 Sept 2022
ISHARES MSCI INDIA SMALL-CAP ETF	block	Buy	6542	3152.55	19 Sept 2022

Astrazeneca Pharma India Ltd News

AstraZeneca Pharma India Gets CDSCO Nod for Calquence in MCL

AstraZeneca Pharma India receives CDSCO approval for broader use of Calquence in treating Mantle Cell Lymphoma, marking a significant regulatory milestone.

21 May 2026

companies

AstraZeneca Board meets May 26

AstraZeneca Pharma India Limited board meets on May 26, 2026, to consider FY26 audited results and dividend. Trading window closed from March 16 to May 28.

20 May 2026

companies

AstraZeneca Pharma India Approves Office Shift to Maharashtra

AstraZeneca Pharma India shareholders approved shifting registered office from Karnataka to Maharashtra via postal ballot, with 99.99% votes in favour, declared May 12, 2026.

13 May 2026

companies

AstraZeneca Pharma India Shareholders Approve Office Shift

AstraZeneca Pharma India shareholders approved shifting registered office from Karnataka to Maharashtra via postal ballot, with 99.99% votes in favour, declared May 12, 2026.

12 May 2026

companies

AstraZeneca Pharma India Shareholders Approve Office Shift

AstraZeneca Pharma India shareholders approved shifting registered office from Karnataka to Maharashtra via postal ballot, with 99.99% votes in favour, declared May 12, 2026.

12 May 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Asset Management Companies

Popular Stocks

Indian Indices

Sector Wise Stocks

IPO

Share Market

Best MF Schemes

Platforms

Resources

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800